Backos May, Rai Raj, Regan Lesley
Department of Reproductive Science and Medicine, Imperial College School of Medicine at St Mary's Hospital, London W2 1NY, UK.
Hum Fertil (Camb). 2002 Feb;5(1):30-4. doi: 10.1080/1464727992000199731.
Antiphospholipid antibodies (aPL) are an established cause of recurrent pregnancy loss. As defective embryonic implantation is a common link between unexplained infertility and recurrent miscarriage, interest has focused on the potential relationship between aPL and implantation failure after in vitro fertilization and embryo transfer (IVF-ET). This review critically examines the published data to determine whether women undergoing IVF-ET should be routinely screened for aPL. Although most studies have reported an increased prevalence of aPL among women undergoing IVF-ET, prospective studies examining the effect of aPL on the outcome of IVF-ET demonstrate that these antibodies do not significantly affect either the implantation or ongoing pregnancy rates. The increased prevalence of aPL among women with infertility is therefore likely to be part of a generalized autoimmune disturbance associated with infertility. Hence routine screening for aPL among women undergoing IVF-ET is not warranted and therapeutic interventions should be used only in well designed randomized controlled trials.
抗磷脂抗体(aPL)是反复流产的既定病因。由于胚胎植入缺陷是不明原因不孕症和反复流产的共同环节,人们的兴趣集中在aPL与体外受精-胚胎移植(IVF-ET)后植入失败之间的潜在关系上。这篇综述批判性地审视了已发表的数据,以确定接受IVF-ET的女性是否应常规筛查aPL。尽管大多数研究报告称接受IVF-ET的女性中aPL的患病率有所增加,但检验aPL对IVF-ET结局影响的前瞻性研究表明,这些抗体对植入率或持续妊娠率均无显著影响。因此,不孕症女性中aPL患病率的增加可能是与不孕症相关的全身性自身免疫紊乱的一部分。因此,不建议对接受IVF-ET的女性常规筛查aPL,仅应在设计良好的随机对照试验中使用治疗干预措施。